Stipple Bio
Stipple Bio is a biotechnology company that offers cellular profiling and target discovery with epitope resolution.
- Company typePrivate
- Founded2022
- HeadquartersCambridge, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Stipple Bio does
Stipple Bio is a biotech company that focuses on advancing cellular profiling and target discovery using epitope-level resolution technologies. It develops proprietary platforms that analyze cellular interactions, enabling researchers to identify precise therapeutic targets for drug development. The company’s approach is particularly applied in oncology, where it aims to discover tumor-specific cell surface epitopes to create safer and more effective treatments. Its “Pointillist” platform is designed to map these epitopes with high precision, helping overcome limitations of traditional therapies such as off-target toxicity.
Stipple Bio firmographics
Firmographics- Name
- Stipple Bio
- Legal name
- Stipple Bio, Inc
- Website
- https://www.stipple.bio
- Company type
- Private
- Founded year
- 2022
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Stipple Bio is a biotechnology company that offers cellular profiling and target discovery with epitope resolution.
- Ownership category
- akta.pro rank
Stipple Bio industry classification
Industry- Product category
- Precision Oncology Therapeutics
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)
- akta.pro secondary industries
- Oncology Specialty Pharmaceuticals (HLAIACAA), Single-Cell & Spatial Omics Discovery Platforms (target ID/validation, functional profiling) (HLAAAIAF)
Keywords
Where Stipple Bio is headquartered
LocationHeadquarters
- HQ city
- Cambridge
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Stipple Bio business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Marketing or Sales, Others
Revenue model
- Drug Commercialization: Pre-revenue biotechnology company. Revenue will be generated through commercialization of pipeline candidates including lead program STP-100, an Antibody Drug Conjugate for precision oncology. As a clinical-stage company, no product revenue is currently generated.
- Licensing and Milestone Payments: Lonza partnership structured with upfront, clinical, regulatory, and commercial milestone payments plus royalties on net sales of resulting ADC products. Strategic partnerships may generate additional licensing revenue streams.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
Stipple Bio product offering
Product offeringCore offering
Stipple Bio develops precision oncology therapeutics by using its proprietary Pointillist Platform to identify tumor-specific cell surface epitopes that distinguish cancer cells from healthy tissue. The company is building a pipeline of epitope-directed medicines, with lead candidate STP-100, a novel Antibody Drug Conjugate (ADC), advancing toward Phase 1 clinical studies expected in early 2027. Its approach is designed to overcome the on-target/off-tumor toxicity that limits conventional targeted cancer therapies.
Product overview
Stipple Bio is a precision oncology biotechnology company built around its proprietary Pointillist Platform, which identifies tumor-specific cell surface epitopes for drug discovery. The company is developing a pipeline of next-generation precision oncology medicines, with its lead candidate STP-100, a novel Antibody Drug Conjugate (ADC), expected to enter clinical studies in early 2027. The Pointillist Platform enables epitope-level targeting that differentiates tumor cells from healthy tissue, addressing the therapeutic index limitations of conventional targeted therapies.
Differentiator
Problem solved
Functional benefit
Products and services
- STP-100
Quantifiable outcome
- Lead candidate STP-100 expected to enter clinical studies in early 2027
- +1 more outcomes
Companies that use Stipple Bio
Customer profileSegments2 records
Ideal customer profiles2 records
Stipple Bio technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Stipple Bio partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- LonzacoreMulti-target licensing agreement granting Stipple Bio access to Lonza's clinically validated ADC technology platform including GlycoConnect conjugation technology, HydraSpace polar spacer technology, and toxSYN linker payload technologies. Lonza is eligible to receive upfront, clinical, regulatory, and commercial milestone payments plus royalties on net sales. Collaboration combines Stipple Bio's epitope discovery capabilities with Lonza's bioconjugation and manufacturing capabilities to advance precision oncology ADC therapies including lead program STP-100.
Scale indicators2 records
Recent moves6 records
Expansion highlights5 records
Stipple Bio competitors and assessment
Company assessmentDirect peers
- CytomX Therapeutics: Clinical-stage oncology biotech developing Probody™-drug conjugates and other conditionally activated therapeutics. Directly comparable to Stipple Bio given shared focus on tumor-selective targeting, ADC/biologic modalities, and overlapping leadership pedigree (Stipple CEO and CBO are former CytomX executives).
- Bolt Biotherapeutics: Clinical-stage immuno-oncology company developing next-generation ADCs and ISACs that combine tumor-targeting antibodies with immune stimulation. Closely comparable to Stipple Bio as a targeted oncology ADC platform company pursuing improved therapeutic index through novel conjugation approaches.
- Mersana Therapeutics: Clinical-stage company developing innovative ADCs with proprietary payload and linker platforms (Dolasynthen, Immunosynthen) for oncology. Highly comparable to Stipple Bio as an ADC-platform company focused on improving therapeutic index through novel chemistry.
- Pyxis Oncology: Clinical-stage oncology company building a pipeline of ADCs and immuno-oncology therapeutics with a focus on difficult-to-drug targets. Comparable to Stipple Bio as a precision oncology platform developing targeted therapeutics against tumor-selective antigens.
Broad incumbents
- ImmunoGen (AbbVie): Pioneer in ADC technology with approved drug (Elahere) and broad clinical pipeline, now part of AbbVie. Comparable as the established incumbent in the ADC space against which Stipple Bio's epitope-targeted ADCs will compete for partnerships and clinical differentiation.
Emerging players
- ProfoundBio: Clinical-stage ADC platform company developing next-generation antibody-drug conjugates with proprietary linker-payload technology. Comparable to Stipple Bio as a similarly positioned emerging ADC developer pursuing improved therapeutic index through novel conjugation chemistry.
- Adagene: Clinical-stage oncology company leveraging AI-driven antibody discovery (POWER platform) to generate conditionally activated antibodies and bispecifics. Comparable to Stipple Bio as a platform-based oncology developer focused on tumor-selective targeting.
- Werewolf Therapeutics: Clinical-stage oncology company developing tumor-selective 'PREDATOR' therapeutics, including masked cytokines and ADCs. Comparable to Stipple Bio given shared focus on improving therapeutic index via tumor-selective activation and targeted oncology payloads.
- Compass Therapeutics: Clinical-stage oncology biotech developing a pipeline of bispecific antibodies and ADCs. Comparable to Stipple Bio as a clinical-stage targeted oncology platform with overlapping investor base and parallel modality focus.
- Black Diamond Therapeutics: Clinical-stage precision oncology company targeting allosteric mutations and difficult-to-drug oncology targets. Comparable to Stipple Bio as a target-discovery-driven precision oncology platform pursuing differentiated therapeutic concepts.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks5 records
Key highlights6 records
Customer concentration
Stipple Bio social profiles
Digital presenceStipple Bio financial estimates
Financial estimateRevenue estimate
Valuation estimate
Stipple Bio leadership team
Management profileNumber of profiles
Profiles6 records
Stipple Bio funding detail
Funding detailFunding overview
Funding rounds4 records
Investors8 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Stipple Bio M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Stipple Bio
What does Stipple Bio do?
Stipple Bio develops precision oncology therapeutics by using its proprietary Pointillist Platform to identify tumor-specific cell surface epitopes that distinguish cancer cells from healthy tissue. The company is building a pipeline of epitope-directed medicines, with lead candidate STP-100, a novel Antibody Drug Conjugate (ADC), advancing toward Phase 1 clinical studies expected in early 2027. Its approach is designed to overcome the on-target/off-tumor toxicity that limits conventional targeted cancer therapies.
Is Stipple Bio a public or private company?
Stipple Bio is a private company. It is classified as venture growth investor backed and is currently operating.
When was Stipple Bio founded?
Stipple Bio was founded in 2022. It employs 1 to 10 people.
Where is Stipple Bio based?
Stipple Bio is headquartered in Cambridge, United States, in the North America region.
How does Stipple Bio make money?
Two revenue lines are on record. Drug Commercialization is the primary driver. The others are licensing and Milestone Payments.
Who are Stipple Bio's main competitors?
Direct peers on record are CytomX Therapeutics, Bolt Biotherapeutics, Mersana Therapeutics and Pyxis Oncology. ImmunoGen (AbbVie) is listed as a broad incumbent. Emerging players are ProfoundBio, Adagene, Werewolf Therapeutics, Compass Therapeutics and Black Diamond Therapeutics.
Does Stipple Bio have an API?
No public API is recorded for Stipple Bio.
What industry is Stipple Bio in?
Stipple Bio's product category is Precision Oncology Therapeutics. Its primary akta.pro industry code is HLAAAIAI, Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation), with a secondary code of HLAIACAA, Oncology Specialty Pharmaceuticals. Its NAICS code is 541714 and its SIC code is 2834.